

# Endocrine

*“If you skew the endocrine system, you lose the pathways to self.”*  
—Hilary Mantel

*“Sometimes you need a little crisis to get your adrenaline flowing and help you realize your potential.”*  
—Jeannette Walls, *The Glass Castle*

*“Chocolate causes certain endocrine glands to secrete hormones that affect your feelings and behavior by making you happy.”*  
—Elaine Sherman, *Book of Divine Indulgences*

The endocrine system comprises widely distributed organs that work in a highly integrated manner to orchestrate a state of hormonal equilibrium within the body. Generally speaking, endocrine diseases can be classified either as diseases of underproduction or overproduction, or as conditions involving the development of mass lesions—which themselves may be associated with underproduction or overproduction of hormones. Therefore, study the endocrine system first by learning the glands, their hormones, and their regulation, and then by integrating disease manifestations with diagnosis and management. Take time to learn the multisystem connections.

► Embryology	334
► Anatomy	335
► Physiology	336
► Pathology	346
► Pharmacology	362

## ► ENDOCRINE—EMBRYOLOGY

**Thyroid development**


Thyroid diverticulum arises from floor of primitive pharynx and descends into neck. Connected to tongue by thyroglossal duct, which normally disappears but may persist as cysts or the pyramidal lobe of thyroid. Foramen cecum is normal remnant of thyroglossal duct.

Most common ectopic thyroid tissue site is the tongue (lingual thyroid). Removal may result in hypothyroidism if it is the only thyroid tissue present.

Thyroglossal duct cyst **A** presents as an anterior midline neck mass that moves with swallowing or protrusion of the tongue (vs persistent cervical sinus leading to pharyngeal cleft cyst in lateral neck).

Thyroid follicular cells derived from endoderm.

Parafollicular cells arise from 4th pharyngeal pouch.



## ► ENDOCRINE—ANATOMY

**Pituitary gland****Anterior pituitary**  
(adenohypophysis)

Secretes FSH, LH, ACTH, TSH, prolactin, GH, and  $\beta$ -endorphin. Melanotropin (MSH) secreted from intermediate lobe of pituitary. Derived from oral ectoderm (Rathke pouch).

- $\alpha$  subunit—hormone subunit common to TSH, LH, FSH, and hCG.
- $\beta$  subunit—determines hormone specificity.


**Pro**opiomelanocortin derivatives— $\beta$ -endorphin, ACTH, and MSH. Go **pro** with a **BAM**!  
**FLAT PiG**: FSH, LH, ACTH, TSH, PRL, GH.  
**B-FLAT**: Basophils—FSH, LH, ACTH, TSH.  
**Acid PiG**: Acidophils — PRL, GH.

**Posterior pituitary**  
(neurohypophysis)

Stores and releases vasopressin (antidiuretic hormone, or ADH) and oxytocin, both made in the hypothalamus (supraoptic and paraventricular nuclei) and transported to posterior pituitary via neurophysins (carrier proteins). Derived from **neuro**ectoderm.

**Adrenal cortex and medulla**

Adrenal cortex (derived from mesoderm) and medulla (derived from neural crest).

ANATOMY	HISTOLOGY	1° REGULATION BY	HORMONE CLASS	1° HORMONE PRODUCED
	Zona <b>G</b> lomerulosa	Angiotensin II	Mineralocorticoids	Aldosterone
	Zona <b>F</b> asciculata	ACTH, CRH	Glucocorticoids	Cortisol
	Zona <b>R</b> eticularis	ACTH, CRH	Androgens	DHEA
	MEDULLA Chromaffin cells	Preganglionic sympathetic fibers	Catecholamines	Epi, NE

**GFR** corresponds with **s**alt (mineralocorticoids), **s**ugar (glucocorticoids), and **s**ex (androgens).  
 “The deeper you go, the sweeter it gets.”


**Endocrine pancreas**  
**cell types**

Islets of Langerhans are collections of  $\alpha$ ,  $\beta$ , and  $\delta$  endocrine cells. Islets arise from pancreatic buds.

$\alpha$  = gluc **$\alpha$** gon (peripheral)

$\beta$  = insulin (central)


$\delta$  = somatostatin (interspersed)




## ► ENDOCRINE—PHYSIOLOGY

## Hypothalamic-pituitary hormones

HORMONE	FUNCTION	CLINICAL NOTES
<b>ADH</b>	↑ water permeability of distal convoluted tubule and collecting duct cells in kidney to ↑ water reabsorption	Stimulus for secretion is ↑ plasma osmolality, except in SIADH, in which ADH is elevated despite ↓ plasma osmolality
<b>CRH</b>	↑ ACTH, MSH, β-endorphin	↓ in chronic exogenous steroid use
<b>Dopamine</b>	↓ prolactin, TSH	Also called prolactin-inhibiting factor Dopamine antagonists (eg, antipsychotics) can cause galactorrhea due to hyperprolactinemia
<b>GHRH</b>	↑ GH	Analog (tesamorelin) used to treat HIV-associated lipodystrophy
<b>GnRH</b>	↑ FSH, LH	Suppressed by hyperprolactinemia Tonic GnRH analog (eg, leuprolide) suppresses hypothalamic–pituitary–gonadal axis. Pulsatile GnRH leads to puberty, fertility
<b>MSH</b>	↑ melanogenesis by melanocytes	Causes hyperpigmentation in Cushing disease, as MSH and ACTH share the same precursor molecule, proopiomelanocortin
<b>Oxytocin</b>	Causes uterine contractions during labor. Responsible for milk letdown reflex in response to suckling.	Modulates fear, anxiety, social bonding, mood, and depression
<b>Prolactin</b>	↓ GnRH Stimulates lactogenesis.	Pituitary prolactinoma → amenorrhea, osteoporosis, hypogonadism, galactorrhea Breastfeeding → ↑ prolactin → ↓ GnRH → delayed postpartum ovulation (natural contraception)
<b>Somatostatin</b>	↓ GH, TSH	Also called growth hormone inhibiting hormone (GHIH) Analogues used to treat acromegaly
<b>TRH</b>	↑ TSH, prolactin	↑ TRH (eg, in 1°/2° hypothyroidism) may increase prolactin secretion → galactorrhea



## Growth hormone



Also called somatotropin. Secreted by anterior pituitary. Stimulates linear growth and muscle mass through IGF-1 (somatomedin C) secretion by liver. ↑ insulin resistance (diabetogenic). Released in pulses in response to growth hormone-releasing hormone (GHRH). Secretion ↑ during exercise, deep sleep, puberty, hypoglycemia. Secretion ↓ by glucose, somatostatin, somatomedin (regulatory molecule secreted by liver in response to GH acting on target tissues). Excess secretion of GH (eg, pituitary adenoma) may cause acromegaly (adults) or gigantism (children). Treatment: somatostatin analogs (eg, octreotide) or surgery.

## Antidiuretic hormone

Also called vasopressin.

SOURCE	Synthesized in hypothalamus (supraoptic and paraventricular nuclei), stored and secreted by posterior pituitary.	
FUNCTION	Regulates blood pressure ( $V_1$ -receptors) and serum osmolality ( $V_2$ -receptors). Primary function is serum osmolality regulation (ADH ↓ serum osmolality, ↑ urine osmolality) via regulation of aquaporin channel insertion in principal cells of renal collecting duct.	ADH level is ↓ in central diabetes insipidus (DI), normal or ↑ in nephrogenic DI. Nephrogenic DI can be caused by mutation in $V_2$ -receptor. Desmopressin (ADH analog) is a treatment for central DI and nocturnal enuresis.
REGULATION	Plasma osmolality ( $1^\circ$ ); hypovolemia.	

**Prolactin****SOURCE**

Secreted mainly by anterior pituitary.

Structurally homologous to growth hormone.

**FUNCTION**

Stimulates milk production in breast; inhibits ovulation in females and spermatogenesis in males by inhibiting GnRH synthesis and release.


Excessive amounts of prolactin associated with ↓ libido.

**REGULATION**

Prolactin secretion from anterior pituitary is tonically inhibited by dopamine from tuberoinfundibular pathway of hypothalamus. Prolactin in turn inhibits its own secretion by ↑ dopamine synthesis and secretion from hypothalamus. TRH ↑ prolactin secretion (eg, in 1° or 2° hypothyroidism).

Dopamine agonists (eg, bromocriptine) inhibit prolactin secretion and can be used in treatment of prolactinoma.

Dopamine antagonists (eg, most antipsychotics, metoclopramide) and estrogens (eg, OCPs, pregnancy) stimulate prolactin secretion.



**Thyroid hormones**

Thyroid produces triiodothyronine ( $T_3$ ) and thyroxine ( $T_4$ ), iodine-containing hormones that control the body's metabolic rate.

**SOURCE**

Follicles of thyroid. 5'-deiodinase converts  $T_4$  (the major thyroid product) to  $T_3$  in peripheral tissue (5, 4, 3). Peripheral conversion is inhibited by glucocorticoids,  $\beta$ -blockers, and propylthiouracil (PTU). Reverse  $T_3$  ( $rT_3$ ) is a metabolically inactive byproduct of the peripheral conversion of  $T_4$  and its production is increased by growth hormone and glucocorticoids. Functions of thyroid peroxidase include oxidation, organification of iodine, and coupling of monoiodotyrosine (MIT) and diiodotyrosine (DIT). Inhibited by PTU and methimazole.  $DIT + DIT = T_4$ .  $DIT + MIT = T_3$ . Wolff-Chaikoff effect—protective autoregulation; sudden exposure to excess iodine temporarily turns off thyroid peroxidase  $\rightarrow \downarrow T_3/T_4$  production.

**FUNCTION**

Only free hormone is active.  $T_3$  binds nuclear receptor with greater affinity than  $T_4$ .  $T_3$  functions —7 B's:

- **B**rain maturation
- **B**one growth (synergism with GH)
- **$\beta$** -adrenergic effects.  $\uparrow \beta_1$  receptors in heart  $\rightarrow \uparrow$  CO, HR, SV, contractility;  $\beta$ -blockers alleviate adrenergic symptoms in thyrotoxicosis
- **B**asal metabolic rate  $\uparrow$  (via  $\uparrow Na^+/K^+$ -ATPase  $\rightarrow \uparrow O_2$  consumption, RR, body temperature)
- **B**lood sugar ( $\uparrow$  glycogenolysis, gluconeogenesis)
- **B**reak down lipids ( $\uparrow$  lipolysis)
- Stimulates surfactant synthesis in **B**abies

**REGULATION**



TRH  $\rightarrow \oplus$  TSH release  $\rightarrow \oplus$  follicular cells. Thyroid-stimulating immunoglobulin (TSI) may  $\oplus$  follicular cells in Graves disease.

Negative feedback primarily by free  $T_3/T_4$ :

- Anterior pituitary  $\rightarrow \downarrow$  sensitivity to TRH
- Hypothalamus  $\rightarrow \downarrow$  TRH secretion

Thyroxine-binding globulin (TBG) binds most  $T_3/T_4$  in blood. Bound  $T_3/T_4$  = inactive.

- $\uparrow$  TBG in pregnancy, OCP use (estrogen  $\rightarrow \uparrow$  TBG)  $\rightarrow \uparrow$  total  $T_3/T_4$
- $\downarrow$  TBG in steroid use, nephrotic syndrome



## Parathyroid hormone

## SOURCE

Chief cells of parathyroid

## FUNCTION

$\uparrow$  free  $\text{Ca}^{2+}$  in the blood ( $1^\circ$  function)  
 $\uparrow$   $\text{Ca}^{2+}$  and  $\text{PO}_4^{3-}$  absorption in GI system  
 $\uparrow$   $\text{Ca}^{2+}$  and  $\text{PO}_4^{3-}$  from bone resorption  
 $\uparrow$   $\text{Ca}^{2+}$  reabsorption from DCT  
 $\downarrow$   $\text{PO}_4^{3-}$  reabsorption in PCT  
 $\uparrow$   $1,25\text{-(OH)}_2\text{D}_3$  (calcitriol) production by activating  $1\alpha$ -hydroxylase in **PCT** (tri) to make  $\text{D}_3$  in the **PCT**

PTH  $\uparrow$  serum  $\text{Ca}^{2+}$ ,  $\downarrow$  serum  $\text{PO}_4^{3-}$ ,  $\uparrow$  urine  $\text{PO}_4^{3-}$ ,  $\uparrow$  urine cAMP


$\uparrow$  RANK-L (receptor activator of NF- $\kappa$ B ligand) secreted by osteoblasts and osteocytes; binds RANK (receptor) on osteoclasts and their precursors to stimulate osteoclasts and  $\uparrow$   $\text{Ca}^{2+}$   $\rightarrow$  bone resorption (intermittent PTH release can also stimulate bone formation)

**PTH** = **P**hosphate-**T**rashing **H**ormone

PTH-related peptide (PTHrP) functions like PTH and is commonly increased in malignancies (eg, squamous cell carcinoma of the lung, renal cell carcinoma)

## REGULATION

$\downarrow$  serum  $\text{Ca}^{2+} \rightarrow \uparrow$  PTH secretion  
 $\uparrow$  serum  $\text{PO}_4^{3-} \rightarrow \uparrow$  PTH secretion  
 $\downarrow$  serum  $\text{Mg}^{2+} \rightarrow \uparrow$  PTH secretion  
 $\downarrow\downarrow$  serum  $\text{Mg}^{2+} \rightarrow \downarrow$  PTH secretion  
 Common causes of  $\downarrow$   $\text{Mg}^{2+}$  include diarrhea, aminoglycosides, diuretics, alcohol use disorder





**Calcium homeostasis**

Plasma  $\text{Ca}^{2+}$  exists in three forms:

- Ionized/free (~ 45%, active form)
- Bound to albumin (~ 40%)
- Bound to anions (~ 15%)

↑ pH (less  $\text{H}^+$ ) → albumin binds more  $\text{Ca}^{2+}$  → ↓ ionized  $\text{Ca}^{2+}$  (eg, cramps, pain, paresthesias, carpopedal spasm) → ↑ PTH

↓ pH (more  $\text{H}^+$ ) → albumin binds less  $\text{Ca}^{2+}$  → ↑ ionized  $\text{Ca}^{2+}$  → ↓ PTH

Ionized/free  $\text{Ca}^{2+}$  is 1° regulator of PTH; changes in pH alter PTH secretion, whereas changes in albumin concentration do not

**Calcitonin**


SOURCE	Parafollicular cells (C cells) of thyroid.	Calcitonin opposes actions of PTH. Not important in normal $\text{Ca}^{2+}$ homeostasis Calcitonin <b>tones</b> down serum $\text{Ca}^{2+}$ levels and keeps it in <b>bones</b>
FUNCTION	↓ bone resorption.	
REGULATION	↑ serum $\text{Ca}^{2+}$ → ↑ calcitonin secretion.	

**Glucagon**

SOURCE	Made by $\alpha$ cells of pancreas.
FUNCTION	Promotes glycogenolysis, gluconeogenesis, lipolysis, ketogenesis. Elevates blood sugar levels to maintain homeostasis when bloodstream glucose levels fall too low (ie, fasting state).
REGULATION	Secreted in response to hypoglycemia. Inhibited by insulin, amylin, somatostatin, hyperglycemia.

## Insulin

### SYNTHESIS



### FUNCTION

Binds **ins**ulin receptors (tyrosine kinase activity **1**), **ind**ucing glucose uptake (carrier-mediated transport) **into** insulin-dependent tissue **2** and gene transcription.

Anabolic effects of insulin:

- ↑ glucose transport in skeletal muscle and adipose tissue
- ↑ glycogen synthesis and storage
- ↑ triglyceride synthesis
- ↑ Na<sup>+</sup> retention (kidneys)
- ↑ protein synthesis (muscles)
- ↑ cellular uptake of K<sup>+</sup> and amino acids
- ↓ glucagon release
- ↓ lipolysis in adipose tissue

Unlike glucose, insulin does not cross placenta.

Insulin-dependent glucose transporters:

- GLUT4: adipose tissue, striated muscle (exercise can also ↑ GLUT4 expression)

Insulin-independent transporters:

- GLUT1: RBCs, brain, cornea, placenta
- GLUT2 (**bi**directional): β islet cells, liver, kidney, GI tract (think **2**-way street)
- GLUT3: brain, placenta
- GLUT5 (fructose): spermatocytes, GI tract
- SGLT1/SGLT2 (Na<sup>+</sup>-glucose cotransporters): kidney, small intestine



Brain prefers glucose, but may use ketone bodies during starvation. RBCs utilize glucose, as they lack mitochondria for aerobic metabolism.

**BRICK LIPS** (insulin-independent glucose uptake): **B**rain, **R**BCs, **I**ntestine, **C**ornea, **K**idney, **L**iver, **I**slet (β) cells, **P**lacenta, **S**permatocytes.

### REGULATION

Glucose is the major regulator of insulin release. ↑ insulin response with oral vs IV glucose due to incretins (eg, glucagon-like peptide 1 [GLP-1], glucose-dependent insulinotropic polypeptide [GIP]), which are released after meals and ↑ β cell sensitivity to glucose. Release ↓ by α<sub>2</sub>, ↑ by β<sub>2</sub> stimulation (**2** = regulates **ins**ulin).

Glucose enters β cells **3** → ↑ ATP generated from glucose metabolism **4** closes K<sup>+</sup> channels (target of sulfonylureas) **5** and depolarizes β cell membrane **6**. Voltage-gated Ca<sup>2+</sup> channels open → Ca<sup>2+</sup> influx **7** and stimulation of insulin exocytosis **8**.





**Cortisol**

## SOURCE

Adrenal zona fasciculata.


## FUNCTION

- ↑ **A**ppetite
- ↑ **B**lood pressure:
  - Upregulates  $\alpha_1$ -receptors on arterioles  
→ ↑ sensitivity to norepinephrine and epinephrine (permissive action)
  - At high concentrations, can bind to mineralocorticoid (aldosterone) receptors
- ↑ **I**nsulin resistance (diabetogenic)
- ↑ **G**luconeogenesis, lipolysis, and proteolysis (↓ glucose utilization)
- ↓ **F**ibroblast activity (poor wound healing, ↓ collagen synthesis, ↑ striae)
- ↓ **I**nflammatory and **I**mmune responses:
  - Inhibits production of leukotrienes and prostaglandins
  - Inhibits WBC adhesion → neutrophilia
  - Blocks histamine release from mast cells
  - Eosinopenia, lymphopenia
  - Blocks IL-2 production
- ↓ **B**one formation (↓ osteoblast activity)

Bound to corticosteroid-binding globulin.

Cortisol is **A BIG FIB**.

Exogenous corticosteroids can cause reactivation of TB and candidiasis (blocks IL-2 production).



## REGULATION

CRH (hypothalamus) stimulates ACTH release (pituitary) → cortisol production in adrenal zona fasciculata. Excess cortisol ↓ CRH, ACTH, and cortisol secretion.

Chronic stress may induce prolonged cortisol secretion, cortisol resistance, impaired immunocompetency, and dysregulation of HPA axis.

**Appetite regulation****Ghrelin**

Stimulates hunger (orexigenic effect) and GH release (via GH secretagog receptor). Produced by stomach. Sleep deprivation, fasting, or Prader-Willi syndrome → ↑ ghrelin production. **G**hrelin makes you **gh**row **hungh**ry. Acts on lateral area of hypothalamus (hunger center) to ↑ appetite.

**Leptin**

Satiety hormone. Produced by adipose tissue. Mutation of leptin gene → severe obesity. Obese people have ↑ leptin due to ↑ adipose tissue but are tolerant or resistant to leptin's anorexigenic effect. Sleep deprivation or starvation → ↓ leptin production. **L**eptin keeps you **thin**. Acts on ventromedial area of hypothalamus (satiety center) to ↓ appetite.


**Endocannabinoids**

Act at cannabinoid receptors in hypothalamus and nucleus accumbens, two key brain areas for the homeostatic and hedonic control of food intake → ↑ appetite. Exogenous cannabinoids cause “the munchies.”

### Signaling pathways of endocrine hormones

<b>cAMP</b>	<b>FSH, LH, ACTH, TSH, CRH, hCG, ADH</b> ( $V_2$ -receptor), <b>MSH, PTH, Calcitonin, Histamine</b> ( $H_2$ -receptor), <b>Glucagon, GHRH</b>	<b>FLAT ChAMPs CHuGG</b>
<b>cGMP</b>	<b>BNP, ANP, EDRF</b> (NO)	<b>BAD GraMPa</b> Think vasodilation and diuresis
<b>IP<sub>3</sub></b>	<b>GnRH, Oxytocin, ADH</b> ( $V_1$ -receptor), <b>TRH, Histamine</b> ( $H_1$ -receptor), <b>Angiotensin II, Gastrin</b>	<b>GOAT HAG</b>
<b>Intracellular receptor</b>	<b>Progesterone, Estrogen, Testosterone, Cortisol, Aldosterone, T<sub>3</sub>/T<sub>4</sub>, Vitamin D</b>	<b>PET CAT in TV</b>
<b>Receptor tyrosine kinase</b>	<b>IGF-1, FGF, PDGF, EGF, Insulin</b>	<b>MAP</b> kinase pathway <b>Get Found In the MAP</b>
<b>Serine/threonine kinase receptor</b>	<b>TGF-<math>\beta</math></b>	
<b>Nonreceptor tyrosine kinase</b>	<b>G-CSF, Erythropoietin, Thrombopoietin</b> <b>Prolactin, Immunomodulators</b> (eg, cytokines IL-2, IL-6, IFN), <b>GH</b>	<b>JAK/STAT</b> pathway Think acidophils and cytokines <b>GET a JAKed PIG</b>

### Signaling pathways of steroid hormones



Steroid hormones are lipophilic and therefore must circulate bound to specific binding globulins, which ↑ their solubility.

In males, ↑ sex hormone-binding globulin (SHBG) lowers free testosterone → gynecomastia.

In females, ↓ SHBG raises free testosterone → hirsutism.

↑ estrogen (eg, OCPs, pregnancy) → ↑ SHBG.

## ► ENDOCRINE—PATHOLOGY

**Syndrome of inappropriate antidiuretic hormone secretion**

Characterized by:

- Excessive free water retention
- Euvolemic hyponatremia with continued urinary  $\text{Na}^+$  excretion
- Urine osmolality > serum osmolality

Body responds to water retention with

↓ aldosterone and ↑ ANP and BNP

→ ↑ urinary  $\text{Na}^+$  secretion → normalization of extracellular fluid volume → euvolemic hyponatremia. Very low serum  $\text{Na}^+$  levels can lead to cerebral edema, seizures. Correct slowly to prevent osmotic demyelination syndrome (formerly called central pontine myelinolysis).

SIADH causes include (**HELD**-up water):

- **H**ead trauma/CNS disorders
- **E**ctopic ADH (eg, small cell lung cancer)
- **L**ung disease
- **D**rugs (eg, SSRIs, carbamazepine, cyclophosphamide)

Treatment: fluid restriction (first line), salt tablets, IV hypertonic saline, diuretics, ADH antagonists (eg, conivaptan, tolvaptan, demeclocycline).

**Primary polydipsia and diabetes insipidus**

Characterized by the production of large amounts of dilute urine +/- thirst. Urine specific gravity <1.006. Urine osmolality usually <300 mOsm/kg. Diabetes insipidus (DI) is classified as central or nephrogenic depending on etiology.

	Primary polydipsia	Central DI	Nephrogenic DI
DEFINITION	Excessive water intake	↓ ADH release	ADH resistance
CAUSES	Psychiatric illnesses, hypothalamic lesions affecting thirst center	Idiopathic, tumors (eg, pituitary), infiltrative diseases (eg, sarcoidosis), trauma, surgery, hypoxic encephalopathy	Hereditary (ADH receptor mutation), drugs (eg, lithium, demeclocycline), hypercalcemia, hypokalemia
SERUM OSMOLALITY	↓	↑	↑
ADH LEVEL	↓ or normal	↓	Normal or ↑
WATER RESTRICTION <sup>a</sup>	Significant ↑ in urine osmolality (>700 mOsm/kg)	No change or slight ↑ in urine osmolality	No change or slight ↑ in urine osmolality
DESMOPRESSIN ADMINISTRATION <sup>b</sup>	—	Significant ↑ in urine osmolality (>50%)	Minimal change in urine osmolality
TREATMENT	Water restriction	Desmopressin	Manage the underlying cause. Low-solute diet, HCTZ, amiloride, indomethacin

<sup>a</sup>No water intake for 2-3 hours followed by hourly measurements of urine volume and osmolality as well as plasma  $\text{Na}^+$  concentration and osmolality.

<sup>b</sup>Desmopressin (ADH analog) is administered if serum osmolality >295-300 mOsm/kg, plasma  $\text{Na}^+ \geq 145$  mEq/L, or urine osmolality does not rise despite ↑ plasma osmolality.

**Hypopituitarism**

Undersecretion of pituitary hormones due to:

- Nonsecreting pituitary adenoma, craniopharyngioma
- **Sheehan syndrome**—ischemic infarct of pituitary following postpartum bleeding; pregnancy-induced pituitary growth → ↑ susceptibility to hypoperfusion. Usually presents with failure to lactate, absent menstruation, cold intolerance
- **Empty sella syndrome**—atrophy or compression of pituitary (which lies in the sella turcica), often idiopathic, common in obese females; associated with idiopathic intracranial hypertension
- **Pituitary apoplexy**—sudden hemorrhage of pituitary gland, often in the presence of an existing pituitary adenoma. Usually presents with sudden onset severe headache, visual impairment (eg, bitemporal hemianopia, diplopia due to CN III palsy), and features of hypopituitarism
- Brain injury
- Radiation

Treatment: hormone replacement therapy (corticosteroids, thyroxine, sex steroids, human growth hormone)

**Acromegaly**

Excess GH in adults. Typically caused by pituitary adenoma.


**FINDINGS**

Large tongue with deep furrows, deep voice, large hands and feet, coarsening of facial features with aging **A**, frontal bossing, diaphoresis (excessive sweating), impaired glucose tolerance (insulin resistance), hypertension. ↑ risk of colorectal polyps and cancer.

↑ GH in children → gigantism (↑ linear bone growth). HF most common cause of death.

**DIAGNOSIS**


↑ serum IGF-1; failure to suppress serum GH following oral glucose tolerance test; pituitary mass seen on brain MRI.

**TREATMENT**

Pituitary adenoma resection. If not cured, treat with octreotide (somatostatin analog), pegvisomant (GH receptor antagonist), or dopamine agonists (eg, cabergoline).

**Hypothyroidism vs hyperthyroidism**


	<b>Hypothyroidism</b>	<b>Hyperthyroidism</b>
<b>METABOLIC</b>	Cold intolerance, ↓ sweating, weight gain (↓ basal metabolic rate → ↓ calorogenesis), hyponatremia (↓ free water clearance)	Heat intolerance, ↑ sweating, weight loss (↑ synthesis of Na <sup>+</sup> -K <sup>+</sup> ATPase → ↑ basal metabolic rate → ↑ calorogenesis)
<b>SKIN/HAIR</b>	Dry, cool skin (due to ↓ blood flow); coarse, brittle hair; diffuse alopecia; brittle nails; puffy facies and generalized nonpitting edema (myxedema <b>A</b> ) due to ↑ GAGs in interstitial spaces → ↑ osmotic pressure → water retention	Warm, moist skin (due to vasodilation); fine hair; onycholysis ( <b>B</b> ); pretibial myxedema in Graves disease
<b>OCULAR</b>	Periorbital edema <b>C</b>	Ophthalmopathy in Graves disease (including periorbital edema, exophthalmos), lid lag/retraction (↑ sympathetic stimulation of levator palpebrae superioris and superior tarsal muscle)
<b>GASTROINTESTINAL</b>	Constipation (↓ GI motility), ↓ appetite	Hyperdefecation/diarrhea (↑ GI motility), ↑ appetite
<b>MUSCULOSKELETAL</b>	Hypothyroid myopathy (proximal weakness, ↑ CK), carpal tunnel syndrome, myoedema (small lump rising on the surface of a muscle when struck with a hammer)	Thyrotoxic myopathy (proximal weakness, normal CK), osteoporosis/↑ fracture rate (T <sub>3</sub> directly stimulates bone resorption)
<b>REPRODUCTIVE</b>	Abnormal uterine bleeding, ↓ libido, infertility	Abnormal uterine bleeding, gynecomastia, ↓ libido, infertility
<b>NEUROPSYCHIATRIC</b>	Hypoactivity, lethargy, fatigue, weakness, depressed mood, ↓ reflexes (delayed/slow relaxing)	Hyperactivity, restlessness, anxiety, insomnia, fine tremors (due to ↑ β-adrenergic activity), ↑ reflexes (brisk)
<b>CARDIOVASCULAR</b>	Bradycardia, dyspnea on exertion (↓ cardiac output)	Tachycardia, palpitations, dyspnea, arrhythmias (eg, atrial fibrillation), chest pain and systolic HTN due to ↑ number and sensitivity of β-adrenergic receptors, ↑ expression of cardiac sarcolemmal ATPase and ↓ expression of phospholamban
<b>LABS</b>	↑ TSH (if 1°) ↓ free T <sub>3</sub> and T <sub>4</sub> Hypercholesterolemia (due to ↓ LDL receptor expression)	↓ TSH (if 1°) ↑ free T <sub>3</sub> and T <sub>4</sub> ↓ LDL, HDL, and total cholesterol






## Hypothyroidism

<b>Hashimoto thyroiditis</b>	<p>Also called chronic autoimmune thyroiditis. Most common cause of hypothyroidism in iodine-sufficient regions. Associated with HLA-DR3, ↑ risk of primary thyroid lymphoma (typically diffuse large B-cell lymphoma).</p> <p>Findings: moderately enlarged, <b>nontender</b> thyroid. May be preceded by transient hyperthyroid state (“Hashitoxicosis”) due to follicular rupture and thyroid hormone release.</p> <p>Serology: ⊕ antithyroid peroxidase (antimicrosomal) and antithyroglobulin antibodies.</p> <p>Histology: Hürthle cells <b>A</b>, lymphoid aggregates with germinal centers <b>B</b>.</p> <p><b>Postpartum thyroiditis</b>—mild, self-limited variant of Hashimoto thyroiditis arising &lt; 1 year after delivery.</p>
<b>Subacute granulomatous thyroiditis</b>	<p>Also called de Quervain thyroiditis. Usually, a self-limited disease. Natural history: transient hyperthyroidism → euthyroid state → hypothyroidism. Often preceded by viral infection.</p> <p>Findings: ↑ ESR, jaw pain, very <b>tender</b> thyroid (de Quervain is associated with <b>pain</b>).</p> <p>Histology: granulomatous inflammation <b>C</b>.</p>
<b>Riedel thyroiditis</b>	<p>Also called invasive fibrous thyroiditis. May be part of IgG<sub>4</sub>-related disease (eg, autoimmune pancreatitis, retroperitoneal fibrosis, noninfectious aortitis). Hypothyroidism occurs in 1/3 of patients.</p> <p>Fibrosis may extend to local structures (eg, trachea, esophagus), mimicking anaplastic carcinoma.</p> <p>Findings: slowly enlarging, hard (rock-like), fixed, <b>nontender</b> thyroid.</p> <p>Histology: thyroid replaced by fibrous tissue and inflammatory infiltrate <b>D</b>.</p>
<b>Congenital hypothyroidism</b>	<p>Formerly called cretinism. Most commonly caused by thyroid dysgenesis (abnormal thyroid gland development; eg, agenesis, hypoplasia, ectopy) or dyshormonogenesis (abnormal thyroid hormone synthesis; eg, mutations in thyroid peroxidase) in iodine-sufficient regions.</p> <p>Findings (<b>6 P</b>'s): <b>p</b>ot-bellied, <b>p</b>ale, <b>p</b>uffy-faced child <b>E</b> with <b>p</b>rotruding umbilicus, <b>p</b>rotuberant tongue <b>F</b>, and <b>p</b>oor brain development.</p>
<b>Other causes</b>	<p>Iodine deficiency (most common cause worldwide; typically presents with goiter <b>G</b>), iodine excess (Wolff-Chaikoff effect), drugs (eg, amiodarone, lithium), nonthyroidal illness syndrome (also called euthyroid sick syndrome; ↓ T<sub>3</sub> with normal/↓ T<sub>4</sub> and TSH in critically ill patients).</p>



## Hyperthyroidism

### Graves disease



Most common cause of hyperthyroidism. Thyroid-stimulating immunoglobulin (IgG, can cause transient neonatal hyperthyroidism; type II hypersensitivity) stimulates TSH receptors on thyroid (hyperthyroidism, diffuse goiter), dermal fibroblasts (pretibial myxedema), and orbital fibroblasts (Graves orbitopathy). Activation of T-cells → lymphocytic infiltration of retroorbital space → ↑ cytokines (eg, TNF- $\alpha$ , IFN- $\gamma$ ) → ↑ fibroblast secretion of hydrophilic GAGs → ↑ osmotic muscle swelling, muscle inflammation, and adipocyte count → exophthalmos **A**. Often presents during stress (eg, pregnancy). Associated with HLA-DR3 and HLA-B8. Histology: tall, crowded follicular epithelial cells; scalloped colloid.

### Toxic multinodular goiter

Focal patches of hyperfunctioning follicular cells distended with colloid working independently of TSH (due to TSH receptor mutations in 60% of cases). ↑ release of T<sub>3</sub> and T<sub>4</sub>. Hot nodules are rarely malignant.

### Thyroid storm

Uncommon but serious complication that occurs when hyperthyroidism is incompletely treated/untreated and then significantly worsens in the setting of acute stress such as infection, trauma, surgery. Presents with agitation, delirium, fever, diarrhea, coma, and tachyarrhythmia (cause of death). May see ↑ LFTs. Treat with the **4 P's**:  $\beta$ -blockers (eg, **p**ropranolol), **p**ropylthiouracil, corticosteroids (eg, **p**rednisolone), **p**otassium iodide (Lugol iodine). Iodide load → ↓ T<sub>4</sub> synthesis → Wolff-Chaikoff effect.


### Jod-Basedow phenomenon

Iodine-induced hyperthyroidism. Occurs when a patient with iodine deficiency and partially autonomous thyroid tissue (eg, autonomous nodule) is made iodine replete. Can happen after iodine IV contrast or amiodarone use. Opposite to Wolff-Chaikoff effect.

### Causes of goiter

Smooth/diffuse: Graves disease, Hashimoto thyroiditis, iodine deficiency, TSH-secreting pituitary adenoma.  
Nodular: toxic multinodular goiter, thyroid adenoma, thyroid cancer, thyroid cyst.


## Thyroid adenoma



Benign solitary growth of the thyroid. Most are nonfunctional (“cold”), can rarely cause hyperthyroidism via autonomous thyroid hormone production (“hot” or “toxic”). Most common histology is follicular (arrows in **A**); absence of capsular or vascular invasion (unlike follicular carcinoma).

**Thyroid cancer**

Typically diagnosed with fine needle aspiration; treated with thyroidectomy. Complications of surgery include hypocalcemia (due to removal of parathyroid glands), transection of recurrent laryngeal nerve during ligation of inferior thyroid artery (leads to dysphagia and dysphonia [hoarseness]), and injury to the external branch of the superior laryngeal nerve during ligation of superior thyroid vascular pedicle (may lead to loss of tenor usually noticeable in professional voice users).


**Papillary carcinoma**

Most common. Empty-appearing nuclei with central clearing (“Orphan Annie” eyes) **A**, psamMoma bodies, nuclear grooves (**Papi** and **Moma** adopted **Orphan Annie**). ↑ risk with *RET/PTC* rearrangements and *BRAF* mutations, childhood irradiation.

Papillary carcinoma: most prevalent, palpable lymph nodes. Good prognosis.

**Follicular carcinoma**

Good prognosis. Invades thyroid capsule and vasculature (unlike follicular adenoma), uniform follicles; hematogenous spread is common. Associated with *RAS* mutation and *PAX8-PPAR-γ* translocations. Fine needle aspiration cytology may not be able to distinguish between follicular adenoma and carcinoma.


**Medullary carcinoma**

From parafollicular “C cells”; produces calcitonin, sheets of polygonal cells in an amyloid stroma **B** (stains with Congo red). Associated with MEN 2A and 2B (*RET* mutations).

**Undifferentiated/  
anaplastic carcinoma**

Older patients; presents with rapidly enlarging neck mass → compressive symptoms (eg, dyspnea, dysphagia, hoarseness); very poor prognosis. Associated with *TP53* mutation.

## Diagnosing parathyroid disease



## Hypoparathyroidism



Due to injury to parathyroid glands or their blood supply (usually during surgery), autoimmune destruction, or DiGeorge syndrome. Findings: tetany, hypocalcemia, hyperphosphatemia.

**Chvostek sign**—tapping of facial nerve (tap the **C**heek) → contraction of facial muscles.

**Trousseau sign**—occlusion of brachial artery with BP cuff (cuff the **T**riceps) → carpal spasm.

**Pseudohypoparathyroidism type 1A**—autosomal dominant, maternally transmitted mutations (imprinted *GNAS* gene). *GNAS*1-inactivating mutation (coupled to PTH receptor) that encodes the G<sub>s</sub> protein α subunit → inactivation of adenylate cyclase when PTH binds to its receptor → end-organ resistance (kidney and bone) to PTH.

Physical findings: Albright hereditary osteodystrophy (shortened 4th/5th digits **A**, short stature, round face, subcutaneous calcifications, developmental delay).

Labs: ↑ PTH, ↓ Ca<sup>2+</sup>, ↑ PO<sub>4</sub><sup>3-</sup>.


**Pseudopseudohypoparathyroidism**—autosomal dominant, paternally transmitted mutations (imprinted *GNAS* gene) but without end-organ resistance to PTH due to normal maternal allele maintaining renal responsiveness to PTH.

Physical findings: same as Albright hereditary osteodystrophy.

Labs: normal PTH, Ca<sup>2+</sup>, PO<sub>4</sub><sup>3-</sup>.

## Lab values in hypocalcemia

DISORDER	Ca <sup>2+</sup>	PO <sub>4</sub> <sup>3-</sup>	PTH
Vitamin D deficiency	↓	↓	↑
Hypoparathyroidism	↓	↑	↓
2° hyperparathyroidism (CKD)	↓	↑	↑
Pseudohypoparathyroidism	↓	↑	↑
Hyperphosphatemia	↓	↑	↑

**Hyperparathyroidism****Primary hyperparathyroidism**

Usually due to parathyroid adenoma or hyperplasia. **Hypercalcemia**, hypercalciuria (renal **stones**), polyuria (**thrones**), hypophosphatemia, ↑ PTH, ↑ ALP, ↑ urinary cAMP. Most often asymptomatic. May present with **bone** pain, weakness, constipation (**“groans”**), abdominal/flank pain (kidney stones, acute pancreatitis), neuropsychiatric disturbances (**“psychiatric overtones”**).

**Osteitis fibrosa cystica**—cystic **bone** spaces filled with brown fibrous tissue **A** (“brown tumor” consisting of osteoclasts and deposited hemosiderin from hemorrhages; causes bone pain). Due to ↑ PTH, classically associated with 1° (but also seen with 2°) hyperparathyroidism.

**“Stones, thrones, bones, groans, and psychiatric overtones.”**

**Secondary hyperparathyroidism**

2° hyperplasia due to ↓  $\text{Ca}^{2+}$  absorption and/or ↑  $\text{PO}_4^{3-}$ , most often in chronic kidney disease (causes hypovitaminosis D and hyperphosphatemia → ↓  $\text{Ca}^{2+}$ ). **Hypocalcemia**, hyperphosphatemia in chronic kidney disease (vs hypophosphatemia with most other causes), ↑ ALP, ↑ PTH.

**Renal osteodystrophy**—renal disease → 2° and 3° hyperparathyroidism → bone lesions.

**Tertiary hyperparathyroidism**

Refractory (autonomous) hyperparathyroidism resulting from chronic kidney disease. ↑↑ PTH, ↑  $\text{Ca}^{2+}$ .

**Familial hypocalciuric hypercalcemia**


Defective G-coupled  $\text{Ca}^{2+}$ -sensing receptors in multiple tissues (eg, parathyroids, kidneys). Higher than normal  $\text{Ca}^{2+}$  levels required to suppress PTH. Excessive renal  $\text{Ca}^{2+}$  reabsorption → mild hypercalcemia and hypocalciuria with normal to ↑ PTH levels.



## Diabetes mellitus

ACUTE MANIFESTATIONS	Polydipsia, polyuria, polyphagia, weight loss, DKA (type 1), hyperosmolar hyperglycemic state (type 2). Rarely, can be caused by unopposed secretion of GH and epinephrine. Also seen in patients on glucocorticoid therapy (steroid diabetes).		
CHRONIC COMPLICATIONS	<p>Nonenzymatic glycation:</p> <ul style="list-style-type: none"> <li>Small vessel disease (diffuse thickening of basement membrane) → retinopathy (hemorrhage, exudates, microaneurysms, vessel proliferation), glaucoma, nephropathy. Nodular glomerulosclerosis → progressive proteinuria (initially microalbuminuria; ACE inhibitors and ARBs are renoprotective. Arteriosclerosis (causing hypertension) → chronic kidney disease.</li> <li>Large vessel atherosclerosis, CAD, peripheral vascular occlusive disease, gangrene → limb loss, cerebrovascular disease. MI most common cause of death.</li> </ul> <p>Osmotic damage (sorbitol accumulation in organs with aldose reductase and ↓ or absent sorbitol dehydrogenase):</p> <ul style="list-style-type: none"> <li>Neuropathy: motor, sensory (glove and stocking distribution), autonomic degeneration (eg, GERD, gastroparesis, diabetic diarrhea).</li> <li>Cataracts.</li> </ul>		
DIAGNOSIS	TEST	DIAGNOSTIC CUTOFF	NOTES
	HbA <sub>1c</sub>	≥ 6.5%	Reflects average blood glucose over prior 3 months (influenced by RBC turnover)
	Fasting plasma glucose	≥ 126 mg/dL	Fasting for > 8 hours
	2-hour oral glucose tolerance test	≥ 200 mg/dL	2 hours after consumption of 75 g of glucose in water
	Random plasma glucose	≥ 200 mg/dL	Presence of hyperglycemic symptoms is required

### Insulin deficiency or severe insulin insensitivity



**Type 1 vs type 2 diabetes mellitus**

	Type 1	Type 2
1° DEFECT	Autoimmune T-cell–mediated destruction of $\beta$ cells (eg, due to presence of glutamic acid decarboxylase antibodies)	↑ resistance to insulin, progressive pancreatic $\beta$ -cell failure
INSULIN NECESSARY IN TREATMENT	Always	Sometimes
AGE (EXCEPTIONS COMMON)	< 30 yr	> 40 yr
ASSOCIATION WITH OBESITY	No	Yes
GENETIC PREDISPOSITION	Relatively weak (50% concordance in identical twins), polygenic	Relatively strong (90% concordance in identical twins), polygenic
ASSOCIATION WITH HLA SYSTEM	Yes, HLA-DR4 and -DR3 (4 – 3 = type 1)	No
GLUCOSE INTOLERANCE	Severe	Mild to moderate
INSULIN SENSITIVITY	High	Low
KETOACIDOSIS	Common	Rare
$\beta$ -CELL NUMBERS IN THE ISLETS	↓	Variable (with amyloid deposits)
SERUM INSULIN LEVEL	↓	↑ initially, but ↓ in advanced disease
CLASSIC SYMPTOMS OF POLYURIA, POLYDIPSIA, POLYPHAGIA, WEIGHT LOSS	Common	Sometimes
HISTOLOGY	Islet leukocytic infiltrate	Islet amyloid polypeptide (IAPP) deposits

**Hyperglycemic emergencies**

	Diabetic ketoacidosis	Hyperosmolar hyperglycemic state
PATHOGENESIS	Insulin noncompliance or ↑ requirements due to ↑ stress (eg, infection) → excess lipolysis and ↑ ketogenesis from ↑ free fatty acids → ketone bodies ( $\beta$ -hydroxybutyrate > acetoacetate). <b>Insulin deficient, ketones present.</b>	Profound hyperglycemia → excessive osmotic diuresis → dehydration and ↑ serum osmolality → HHS. Classically seen in elderly patients with type 2 DM and limited ability to drink. <b>Insulin present, ketones absent.</b>
SIGNS/SYMPTOMS	<b>DKA</b> is <b>D</b> eadly: <b>D</b> elirium/psychosis, <b>K</b> ussmaul respirations (rapid, deep breathing), <b>A</b> bdominal pain/nausea/vomiting, <b>D</b> ehydration. Fruity breath odor due to exhaled acetone.	Thirst, polyuria, lethargy, focal neurologic deficits, seizures.
LABS	Hyperglycemia, ↑ $H^+$ , ↓ $HCO_3^-$ (↑ anion gap metabolic acidosis), ↑ urine and blood ketone levels, leukocytosis. Normal/↑ serum $K^+$ , but depleted intracellular $K^+$ due to transcellular shift from ↓ insulin and acidosis. Osmotic diuresis → ↑ $K^+$ loss in urine → total body $K^+$ depletion.	Hyperglycemia (often > 600 mg/dL), ↑ serum osmolality (> 320 mOsm/kg), normal pH (no acidosis), no ketones. Normal/↑ serum $K^+$ , ↓ intracellular $K^+$ .
COMPLICATIONS	Life-threatening mucormycosis, cerebral edema, cardiac arrhythmias.	Can progress to coma and death if untreated.
TREATMENT	IV fluids, IV insulin, and $K^+$ (to replete intracellular stores). Glucose may be required to prevent hypoglycemia from insulin therapy.	

### Hypoglycemia in diabetes mellitus

Usually occurs in patients treated with insulin or insulin secretagogues (eg, sulfonylureas, meglitinides) in the setting of high-dose treatment, inadequate food intake, and/or exercise.

- Neurogenic/autonomic symptoms: diaphoresis, tachycardia, tremor, anxiety, hunger. May allow perception of ↓ glucose (hypoglycemia awareness).
- Neuroglycopenic symptoms: altered mental status, seizures, death due to insufficient glucose in CNS.

Treatment: simple carbohydrates (eg, glucose tablets, fruit juice), IM glucagon, IV dextrose.

### Cushing syndrome

#### ETIOLOGY

↑ cortisol due to a variety of causes:



- Exogenous corticosteroids → ↓ ACTH → bilateral adrenal atrophy. Most common cause.
- Primary adrenal adenoma, hyperplasia, or carcinoma → ↓ ACTH → atrophy of uninvolved adrenal gland.
- ACTH-secreting pituitary adenoma (Cushing disease); paraneoplastic ACTH secretion (eg, small cell lung cancer, bronchial carcinoids) → bilateral adrenal hyperplasia. Cushing disease is responsible for the majority of endogenous cases of Cushing syndrome.

#### FINDINGS

**CUSHING** Syndrome: ↑ **C**holesterol, ↑ **U**rinary free cortisol, **S**kin changes (thinning, striae **A**), **H**ypertension, **I**mmunosuppression, **N**eoplasm (a cause, not a finding), **G**rowth restriction (in children), ↑ **S**ugar (hyperglycemia, insulin resistance). Also, amenorrhea, moon facies **B**, buffalo hump, osteoporosis, ↑ weight (truncal obesity), hirsutism.

#### DIAGNOSIS

Screening tests include: ↑ free cortisol on 24-hr urinalysis, ↑ late night salivary cortisol, and no suppression with overnight low-dose dexamethasone test.





**Nelson syndrome**

Enlargement of pre-existing ACTH-secreting pituitary adenoma after bilateral adrenalectomy for refractory Cushing disease → ↑ ACTH (hyperpigmentation), mass effect (headaches, bitemporal hemianopia).

Treatment: transsphenoidal resection, postoperative pituitary irradiation for residual tumor.

**Adrenal insufficiency**


Inability of adrenal glands to generate enough glucocorticoids +/- mineralocorticoids for the body's needs. Can be acute or chronic. Symptoms include weakness, fatigue, orthostatic hypotension, muscle aches, weight loss, GI disturbances, sugar and/or salt cravings.

Treatment: glucocorticoid +/- mineralocorticoid replacement.

**Primary adrenal insufficiency**

↓ gland function → ↓ cortisol, ↓ aldosterone → hypotension (hyponatremic volume contraction), hyperkalemia, metabolic acidosis, skin/mucosal hyperpigmentation **A** (↑ melanin synthesis due to ↑ MSH, a byproduct of POMC cleavage). **P**rimary **p**igments the skin/mucosa.

**Addison disease**—chronic 1° adrenal insufficiency; caused by adrenal atrophy or destruction. Most commonly due to autoimmune adrenalitis (developed world) or TB (developing world).

**Secondary and tertiary adrenal insufficiency**


↓ pituitary ACTH secretion (secondary) or ↓ hypothalamic CRH secretion (tertiary). No hyperkalemia (aldosterone synthesis preserved due to functioning adrenal gland, intact RAAS), no hyperpigmentation.

2° adrenal insufficiency is due to pituitary pathologies, 3° adrenal insufficiency is most commonly due to abrupt cessation of chronic steroid therapy (HPA suppression). **T**ertiary from **t**reatment.

**Acute adrenal insufficiency**

Also called adrenal (addisonian) crisis; often precipitated by acute stressors that ↑ steroid requirements (eg, infection) in patients with pre-existing adrenal insufficiency or on steroid therapy. May present with acute abdomen, nausea, vomiting, altered mental status, shock.

**Waterhouse-Friderichsen syndrome**—bilateral adrenal hemorrhage often due to meningococemia. May present with acute adrenal insufficiency, fever, petechiae, sepsis.



**Hyperaldosteronism**

Increased secretion of aldosterone from adrenal gland. Clinical features include hypertension, ↓ or normal  $K^+$ , metabolic alkalosis. 1° hyperaldosteronism does not directly cause edema due to aldosterone escape mechanism. However, certain 2° causes of hyperaldosteronism (eg, heart failure) impair the aldosterone escape mechanism, leading to worsening of edema.

**Primary hyperaldosteronism**

Seen in patients with bilateral adrenal hyperplasia or adrenal adenoma (Conn syndrome). ↑ aldosterone, ↓ renin. Leads to treatment-resistant hypertension.

**Secondary hyperaldosteronism**


Seen in patients with renovascular hypertension, juxtaglomerular cell tumors (renin-producing), and edema (eg, cirrhosis, heart failure, nephrotic syndrome).

**Neuroendocrine tumors**

Heterogeneous group of neoplasms originating from neuroendocrine cells (which have traits similar to nerve cells and hormone-producing cells).

Most neoplasms occur in the GI system (eg, carcinoid, gastrinoma), pancreas (eg, insulinoma, glucagonoma), and lungs (eg, small cell carcinoma). Also in thyroid (eg, medullary carcinoma) and adrenals (eg, pheochromocytoma).

Neuroendocrine cells (eg, pancreatic  $\beta$  cells, enterochromaffin cells) share a common biologic function through amine precursor uptake decarboxylase (APUD) despite differences in embryologic origin, anatomic site, and secretory products (eg, chromogranin A, neuron-specific enolase [NSE], synaptophysin, serotonin, histamine, calcitonin). Treatment: surgical resection, somatostatin analogs.

**Neuroblastoma**


Most common tumor of the adrenal medulla in **children**, usually < 4 years old. Originates from **n**eural crest cells. Occurs anywhere along the sympathetic chain.

Most common presentation is abdominal distension and a firm, irregular mass that can cross the midline (vs Wilms tumor, which is smooth and unilateral). Less likely to develop hypertension than with pheochromocytoma (**n**euroblastoma is **n**ormotensive). Can also present with opsoclonus-myoclonus syndrome (“dancing eyes-dancing feet”).

↑ HVA and VMA (catecholamine metabolites) in urine. Homer-Wright rosettes (neuroblasts surrounding a central lumen **A**) characteristic of neuroblastoma and medulloblastoma. Bombesin and **N**SE ⊕. Associated with amplification of **N**-myc oncogene.

## Pheochromocytoma

### ETIOLOGY



Most common tumor of the adrenal medulla in **adults A**. Derived from chromaffin cells (arise from neural crest).

May be associated with germline mutations (eg, *NF-1*, *VHL*, *RET* [MEN 2A, 2B]).

### Rule of 10's:

**10%** malignant

**10%** bilateral

**10%** extra-adrenal (eg, bladder wall, organ of Zuckerkandl)

**10%** calcify

**10%** kids

### SYMPTOMS

Most tumors secrete epinephrine, norepinephrine, and dopamine, which can cause episodic hypertension. May also secrete EPO → polycythemia.

Symptoms occur in “spells”—relapse and remit.

Episodic hyperadrenergic symptoms (**5 P's**):

**P**ressure (↑ BP)

**P**ain (headache)

**P**erspiration

**P**alpitations (tachycardia)

**P**allor

### FINDINGS

↑ catecholamines and metanephrines (eg, homovanillic acid, vanillylmandelic acid) in urine and plasma.

Chromogranin, synaptophysin and NSE ⊕.

### TREATMENT


Irreversible  $\alpha$ -antagonists (eg, phenoxybenzamine) followed by  $\beta$ -blockers prior to tumor resection.  $\alpha$ -blockade must be achieved before giving  $\beta$ -blockers to avoid a hypertensive crisis. **A** before **B**.

**P**henoxybenzamine for **p**heochromocytoma.

### Multiple endocrine neoplasias

All **MEN** syndromes have autosomal **dominant** inheritance.  
The **X-MEN** are **dominant** over villains.

SUBTYPE	CHARACTERISTICS	COMMENTS
<b>MEN 1</b>	<p><b>P</b>ituitary tumors (prolactin or GH)</p> <p><b>P</b>ancreatic endocrine tumors—Zollinger-Ellison syndrome, insulinomas, VIPomas, glucagonomas (rare)</p> <p><b>P</b>arathyroid adenomas</p> <p>Associated with mutation of <i>MEN1</i> (menin, a tumor suppressor, chromosome 11), angiofibromas, collagenomas, meningiomas</p>	
<b>MEN 2A</b>	<p><b>P</b>arathyroid hyperplasia</p> <p>Medullary thyroid carcinoma—neoplasm of parafollicular C cells; secretes calcitonin; prophylactic thyroidectomy required</p> <p><b>P</b>heochromocytoma (secretes catecholamines)</p> <p>Associated with mutation in <i>RET</i> (codes for receptor tyrosine kinase)</p>	
<b>MEN 2B</b>	<p>Medullary thyroid carcinoma</p> <p><b>P</b>heochromocytoma</p> <p>Mucosal neuromas <b>A</b> (oral/intestinal ganglioneuromatosis)</p> <p>Associated with marfanoid habitus; mutation in <i>RET</i> gene</p>	



**MEN 1** = **3 P**'s: **p**ituitary, **p**arathyroid, and **p**ancreas

**MEN 2A** = **2 P**'s: **p**arathyroid and **p**heochromocytoma

**MEN 2B** = **1 P**: **p**heochromocytoma

**Pancreatic islet cell tumors****Insulinoma**

Tumor of pancreatic  $\beta$  cells  $\rightarrow$  overproduction of insulin  $\rightarrow$  hypoglycemia.  
May see Whipple triad: low blood glucose, symptoms of hypoglycemia (eg, lethargy, syncope, diplopia), and resolution of symptoms after normalization of plasma glucose levels. Symptomatic patients have  $\downarrow$  blood glucose and  $\uparrow$  C-peptide levels (vs exogenous insulin use).  $\sim 10\%$  of cases associated with MEN 1 syndrome.

Treatment: surgical resection.


**Glucagonoma**

Tumor of pancreatic  $\alpha$  cells  $\rightarrow$  overproduction of glucagon.  
Presents with **6 D's**: **d**ermatitis (necrolytic migratory erythema), **d**iabetes (hyperglycemia), **D**VT, **d**eclining weight, **d**epression, **d**iarrhea.

Treatment: octreotide, surgical resection.

**Somatostatinoma**

Tumor of pancreatic  $\delta$  cells  $\rightarrow$  overproduction of somatostatin  $\rightarrow$   $\downarrow$  secretion of secretin, cholecystokinin, glucagon, insulin, gastrin, gastric inhibitory peptide (GIP).  
May present with diabetes/glucose intolerance, steatorrhea, gallstones, achlorhydria.  
Treatment: surgical resection; somatostatin analogs (eg, octreotide) for symptom control.

**Carcinoid tumors**

Carcinoid tumors arise from neuroendocrine cells, most commonly in the intestine or lung.  
Neuroendocrine cells secrete 5-HT, which undergoes hepatic first-pass metabolism and enzymatic breakdown by MAO in the lung. If 5-HT reaches the systemic circulation (eg, after liver metastasis), carcinoid tumor may present with **carcinoid syndrome**—episodic flushing, diarrhea, wheezing, right-sided valvular heart disease (eg, tricuspid regurgitation, pulmonic stenosis), niacin deficiency (pellagra).

Histology: prominent rosettes (arrow in **A**), chromogranin A  $\oplus$ , synaptophysin  $\oplus$ .

Treatment: surgical resection, somatostatin analog (eg, octreotide) or tryptophan hydroxylase inhibitor (eg, telotristat) for symptom control.

**Rule of thirds:**

- 1/3** metastasize
- 1/3** present with 2nd malignancy
- 1/3** are multiple

**Zollinger-Ellison syndrome**

Gastrin-secreting tumor (gastrinoma) of duodenum or pancreas. Acid hypersecretion causes recurrent ulcers in duodenum and jejunum. Presents with abdominal pain (peptic ulcer disease, distal ulcers), diarrhea (malabsorption). Positive secretin stimulation test:  $\uparrow$  gastrin levels after administration of secretin, which normally inhibits gastrin release. May be associated with MEN 1.

## ► ENDOCRINE—PHARMACOLOGY


**Diabetes mellitus therapy**

All patients with diabetes mellitus should receive education on diet, exercise, blood glucose monitoring, and complication management. Treatment differs based on the type of diabetes and glycemic control:

- Type 1 DM—insulin replacement
- Type 2 DM—oral agents (metformin is first line), non-insulin injectables, insulin replacement; weight loss particularly helpful in lowering blood glucose
- Gestational DM—insulin replacement if nutrition therapy and exercise alone fail

Regular (short-acting) insulin is preferred for DKA (IV), hyperkalemia (+ glucose), stress hyperglycemia.

These drugs help **To** normalize **pancreatic** function ( -glits, -glins, -glips, -glifs).



DRUG CLASS	MECHANISM	ADVERSE EFFECTS
<b>Insulin preparations</b>		
Rapid acting (1-hr peak): <b>Lispro</b> , <b>Aspart</b> , <b>Glulisine</b> (no <b>LAG</b> )	Bind insulin receptor (tyrosine kinase activity)	Hypoglycemia, lipodystrophy, hypersensitivity reactions (rare), weight gain
Short acting (2–3 hr peak): regular	Liver: ↑ glucose storage as glycogen	
Intermediate acting (4–10 hr peak): NPH	Muscle: ↑ glycogen, protein synthesis	
Long acting (no real peak): detemir, glargine	Fat: ↑ TG storage	
	Cell membrane: ↑ K <sup>+</sup> uptake	
		<p>The graph plots Plasma insulin level (y-axis) against Hours (x-axis, 0 to 18). The curves represent different insulin preparations: Lispro, aspart, and glulisine (rapid-acting) peak early and decline quickly; Regular insulin peaks slightly later; NPH (intermediate-acting) has a broader peak; Detemir and Glargine (long-acting) show a more sustained, lower-level activity over time.</p>

**Diabetes mellitus therapy (continued)**

DRUG CLASS	MECHANISM	ADVERSE EFFECTS
<b>Increase insulin sensitivity</b>		
<b>Biguanides</b> Metformin	Inhibit mGPD → inhibition of hepatic gluconeogenesis and the action of glucagon. ↑ glycolysis, peripheral glucose uptake (↑ insulin sensitivity).	GI upset, lactic acidosis (use with caution in renal insufficiency), vitamin B <sub>12</sub> deficiency. Weight loss (often desired).
<b>Thiazolidinediones</b> “-glits” Pioglitazone, rosiglitazone	Activate PPAR-γ (a nuclear receptor) → ↑ insulin sensitivity and levels of adiponectin → regulation of glucose metabolism and fatty acid storage.	Weight gain, edema, HF, ↑ risk of fractures. Delayed onset of action (several weeks). Rosiglitazone: ↑ risk of MI, cardiovascular death.
<b>Increase insulin secretion</b>		
<b>Sulfonylureas (1st gen)</b> Chlorpropamide, tolbutamide		Disulfiram-like reaction with first-generation sulfonylureas only (rarely used).
<b>Sulfonylureas (2nd gen)</b> Glipizide, glyburide	Close K <sup>+</sup> channels in pancreatic B cell membrane → cell depolarizes → insulin release via ↑ Ca <sup>2+</sup> influx.	Hypoglycemia (↑ risk in renal insufficiency), weight gain.
<b>Meglitinides</b> “-glins” Nateglinide, repaglinide		
<b>Increase glucose-induced insulin secretion</b>		
<b>GLP-1 analogs</b> Exenatide, liraglutide	↓ glucagon release, ↓ gastric emptying, ↑ glucose-dependent insulin release.	Nausea, vomiting, pancreatitis. Weight loss (often desired). ↑ satiety (often desired).
<b>DPP-4 inhibitors</b> “-glips” Linagliptin, saxagliptin, sitagliptin	Inhibit DPP-4 enzyme that deactivates GLP-1 → ↓ glucagon release, ↓ gastric emptying. ↑ glucose-dependent insulin release.	Respiratory and urinary infections, weight neutral. ↑ satiety (often desired).
<b>Decrease glucose absorption</b>		
<b>Sodium-glucose co-transporter 2 inhibitors</b> “-glifs” Canagliflozin, dapagliflozin, empagliflozin	Block reabsorption of glucose in proximal convoluted tubule.	Glucosuria (UTIs, vulvovaginal candidiasis), dehydration (orthostatic hypotension), weight loss. Use with caution in renal insufficiency (↓ efficacy with ↓ GFR).
<b>α-glucosidase inhibitors</b> Acarbose, miglitol	Inhibit intestinal brush-border α-glucosidases → delayed carbohydrate hydrolysis and glucose absorption → ↓ postprandial hyperglycemia.	GI upset, bloating. Not recommended in renal insufficiency.
<b>Others</b>		
<b>Amylin analogs</b> Pramlintide	↓ glucagon release, ↓ gastric emptying.	Hypoglycemia, nausea. ↑ satiety (often desired).

**Thionamides**

Propylthiouracil, methimazole.

MECHANISM	Block thyroid peroxidase, inhibiting the oxidation of iodide as well as the organification and coupling of iodine → inhibition of thyroid hormone synthesis. <b>PTU</b> also blocks 5'-deiodinase → ↓ <b>P</b> eripheral conversion of $T_4$ to $T_3$ .
CLINICAL USE	Hyperthyroidism. <b>PTU</b> used in <b>P</b> rimary (first) trimester of pregnancy (due to methimazole teratogenicity); methimazole used in second and third trimesters of pregnancy (due to risk of PTU-induced hepatotoxicity). Not used to treat Graves ophthalmopathy (treated with corticosteroids).
ADVERSE EFFECTS	Skin rash, agranulocytosis (rare), aplastic anemia, hepatotoxicity. PTU use has been associated with ANCA-positive vasculitis. Methimazole is a possible teratogen (can cause aplasia cutis).

**Levothyroxine, liothyronine**

MECHANISM	Hormone replacement for $T_4$ (levothyroxine) or $T_3$ (liothyronine).
CLINICAL USE	Hypothyroidism, myxedema. May be abused for weight loss. Distinguish exogenous hyperthyroidism from endogenous hyperthyroidism by using a combination of TSH receptor antibodies, radioactive iodine uptake, and/or measurement of thyroid blood flow on ultrasound.
ADVERSE EFFECTS	Tachycardia, heat intolerance, tremors, arrhythmias.

**Hypothalamic/pituitary drugs**

DRUG	CLINICAL USE
Conivaptan, tolvaptan	ADH antagonists SIADH (block action of ADH at $V_2$ -receptor)
Demeclocycline	Interferes with ADH signaling, a tetracycline SIADH
Desmopressin	ADH analog Central DI, von Willebrand disease, sleep enuresis, hemophilia A
GH	GH deficiency, Turner syndrome
Oxytocin	Induction of labor (stimulates uterine contractions), control uterine hemorrhage
Somatostatin (octreotide)	Acromegaly, carcinoid syndrome, gastrinoma, glucagonoma, esophageal varices

**Fludrocortisone**

MECHANISM	Synthetic analog of aldosterone with glucocorticoid effects. <b>Fluid</b> ro cortisone retains <b>fluid</b> .
CLINICAL USE	Mineralocorticoid replacement in 1° adrenal insufficiency.
ADVERSE EFFECTS	Similar to glucocorticoids; also edema, exacerbation of heart failure, hyperpigmentation.



**Cinacalcet**

MECHANISM	Sensitizes <b>calcium</b> -sensing receptor (CaSR) in parathyroid gland to circulating $\text{Ca}^{2+} \rightarrow \downarrow \text{PTH}$ . Pronounce “ <b>Senacalcet</b> .”
CLINICAL USE	2° hyperparathyroidism in patients with CKD receiving hemodialysis, hypercalcemia in 1° hyperparathyroidism (if parathyroidectomy fails), or in parathyroid carcinoma.
ADVERSE EFFECTS	Hypocalcemia.

**Sevelamer**

MECHANISM	Nonabsorbable phosphate binder that prevents phosphate absorption from the GI tract.
CLINICAL USE	Hyperphosphatemia in CKD.
ADVERSE EFFECTS	Hypophosphatemia, GI upset.

**Cation exchange resins** Patiromer, sodium polystyrene sulfonate, zirconium cyclosilicate.

MECHANISM	Bind $\text{K}^+$ in colon in exchange for other cations (eg, $\text{Na}^+$ , $\text{Ca}^{2+}$ ) $\rightarrow \text{K}^+$ excreted in feces.
CLINICAL USE	Hyperkalemia.
ADVERSE EFFECTS	Hypokalemia, GI upset.

▶ NOTES